Radiation Therapy (RT) For Parkinson's Disease (PD)

Overview

About this study

The purpose of this study is to investigate the use of ultra-low, anti-inflammatory doses of radiation therapy (RT) for the treatment of Parkinson's Disease (PD). In this study, the TrueBeam LINAC utilizes a linear accelerator (LINAC) for the delivery of radiation therapy. Dynamic conformal arc (DCA) therapy will be used to deliver a total of five (5) once-a-day radiation treatments (RT) using DaT-SPECT (Dopamine Transporter-Single-Photon Emission Computed Tomography) and MRI imaging to guide radiation treatment planning.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Age ≥ 45 and ≤ 70 years
* Diagnosis of Parkinson's disease by a Movement Disorder Neurologist
* Confirmation of unilateral Parkinson's disease by Dopamine Transporter (DaT) scan
* A score of 2 or less on the modified Hoehn and Yahr scale
* ECOG Performance Status (PS) ≤ 2 (Appendix I).
* No known genetic causes or predisposition to Parkinson's disease or related diseases.
* Ability to complete questionnaires, neurological exam, and follow-up imaging independently or with assistance
* Ability to provide written informed consent
* Willing to provide mandatory blood samples for correlative research purposes
* Willing to return to enrolling institution for follow-up

Exclusion Criteria:

* Concomitant dementia diagnosis or concerns of other memory disorder
* Parkinson's Disease medication changes within the last 3 months
* Receipt of radiation therapy for Parkinson's Disease outside Mayo Clinic, Rochester

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 06/24/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Yasamin Sharifzadeh-Moghaddam, M.D.	Open for enrollment	Contact information: Cancer Center Clinical Trials Referral Office (855) 776-0015

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yasamin Sharifzadeh-Moghaddam, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Clinical Trials